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Abstract
One of the major problems related with anticancer chemotherapy is resistance against anticancer
drugs. The ATP-binding cassette (ABC) transporters are a family of transporter proteins that are
responsible for drug resistance and a low bioavailability of drugs by pumping a variety of drugs out
cells at the expense of ATP hydrolysis. One strategy for reversal of the resistance of tumor cells
expressing ABC transporters is combined use of anticancer drugs with chemosensitizers. In this
review, the physiological functions and structures of ABC transporters, and the development of
chemosensitizers are described focusing on well-known proteins including P-glycoprotein,
multidrug resistance associated protein, and breast cancer resistance protein.
Background
One of the major problems related with anticancer chem-
otherapy is resistance against anticancer drugs. Some can-
cers such as non-small cancer, lung cancer, and rectal
cancer show what is called primary resistance or natural
resistance in which they do not respond to standard
chemotherapy drugs from the beginning. On the other
hand, many types of sensitive tumors respond well to
chemotherapy drugs in the beginning but show acquired
resistance later. Experimentally, drug resistance could be
very specific to the drug used due to abnormal genetic
machinery such as gene amplification within tumor cells
in many cases. Multidrug resistance (MDR) is especially
problematic in acquired drug resistance. MDR is the phe-
nomenon in which cancer cells exposed to one anticancer
drug show resistance to various anticancer drugs that are
structurally and functionally different from the initial
anticancer drug. The most investigated mechanisms with
known clinical significance are: a) activation of trans-
membrane proteins effluxing different chemical sub-
stances from the cells; b) activation of the enzymes of the
glutathione detoxification system; c) alterations of the
genes and the proteins involved into the control of apop-
tosis (especially p53 and Bcl-2). The cell membrane, cyto-
plasm, and nuclear protein participate in these resistance
mechanisms [1]. The resistance mechanism is called typi-
cal MDR or classical MDR when overexpression of the
membrane efflux pumps is involved in MDR. The classical
MDR is due mostly to increased efflux pumps in the cell
membrane of cells pumping anticancer drugs out of cells.
The most typical efflux pumps in the cell membrane is P-
glycoprotein (Pgp) [2] having the molecular weight of
170 KD, due to the gene amplification of the normal
human gene, MDR1. The efflux pump Pgp is responsible
for transporting various xenobiotics (not limited to anti-
cancer drugs) out of cells by using ATP (Fig. 1) [3]. Pgp is
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one of the membrane transporter superfamily having the
ATP-binding cassette (ABC) with well-preserved homol-
ogy of the site where ATP binds. There are more than 100
ABC transporters distributed from prokaryotes to
humans. Forty-eight ABC genes have been reported in
humans, among which the functions of 16 genes have
been determined and 14 genes are related with diseases
present in humans (cystic fibrosis, adrenoleukodystro-
phy, Stargardt's disease, drug-resistant tumors, Dubin-
Johnson syndrome, Byler's disease, progressive familiar
intrahepatic cholestasis, X-linked sideroblastic anemia,
ataxia, and persistent and hyperinsulimenic hypoglyc-
emia in children) http://www.nutrigene.4t.com/
humanabc.htmc[4,5].
Other efflux pumps of the mammalian cell membrane in
ABC superfamily include multidrug resistance-associated
proteins (MRP) [6] and breast cancer resistance proteins
(BCRP; mitoxantrone resistance proteins, MXR) [7,8].
Other than the fact that these resistant proteins belong to
the ABC superfamily, they are quite different with respect
to gene locus, amino acid sequence, structure and sub-
strate (Table 1 and 2). In this review, the physiological
functions and structures of ABC transporters, and
development of chemosensitizers are described focusing
on well-known proteins including Pgp, MRP, and BCRP.
Functions of ABC transporters
Although the physiologic functions of ABC transporters
are not well known, they are expressed constitutively in
not only tumor cells but also normal cells in the digestive
system including the small intestine, large intestine, liver,
and pancreas; epithelial cells in the kidneys, adrenals,
brain, and testes; and endothelial cells (Table 1). From the
aspect of the tissue distribution, ABC transporters are
thought to participate in the absorption and secretion of
endogenous and exogenous substances. Endogenous and
exogenous substrates for ABC transporters reported so far
are summarized in Table 2. Especially, the ABC transport-
ers have shown to function as an efflux pump for lipid,
multiple drugs, natural products and peptides. It is pro-
posed to operate as a hydrophobic vacuum cleaner, expel-
ling non-polar compounds from the membrane bilayer to
the exterior, driven by the energy of ATP hydrolysis [143].
ATP-dependent transbilayer lipid transporters are classi-
fied into cytofacially-directed flippases and exofacially-
directed floppases. Floppase activity has been associated
with the ABC transporters although not all ABC transport-
ers are floppases [144]. Endogenous substrates for Pgp
include corticosterone [145], beta-estradiol 17beta-D-glu-
curonide, an endogenous cholestatic metabolite of estra-
diol [146], 1-O-alkyl-2-acetyl-sn-glycero-3-
phosphocholine (generically platelet-activating factor,
PAF) [147], glutamate [148] and endorphin [149]. It was
also recently reported that Pgp has the function of remov-
ing beta-amyloid, which was reported as the causal sub-
stance of Alzheimer's disease [150,151]. MRP1 effluxes
various conjugated substrates such as leukotriene C4 con-
jugates [152], steroid conjugates [153] and the GSH con-
jugate of aflatoxin B1, which is a mycotoxin [154]. Cells
can, upon hypoxic demand, use BCRP to reduce heme or
porphyrin accumulation, which can be detrimental to
cells [155]. When cancer originates not only from cells
normally expressing efflux pump but also cells having
genes but not expressing, gene expression is initiated due
to the exposure to anticancer drugs, resulting in resistance
to anticancer drugs, eventually interfering with
chemotherapy.
Pgp is mainly present in the apical membrane of intestinal
mucosal membrane and lowers bioavailability of drugs by
preventing the absorption of the drugs. Digoxin, which
shows a low bioavailability and is mainly excreted
through stool in normal mice due to poor absorption in
the mouse intestine, shows a high bioavailability and
mainly excreted through urine in mice with mdr1 knocked
out[156]. The bioavailability of the substrate of Pgp, pacl-
itaxel, also increased significantly in mice with mdr1
knocked out and in mice administered with the Pgp
inhibitor, PSC-833 [157].
Schematic structural organization of P-glycoprotein Figure 1
Schematic structural organization of P-glycoprotein. Each half 
contains a highly hydrophobic domain with 6 transmembrane 
α-helices involved in chemotherapeutic drug efflux, and a 
hydrophilic domain located at the cytoplasmic face of the 
membrane, nucleotide binding domain 1(NBD1) or NMD 2, 
containing an ATP-binding site with cheracteristic Walker 
motifs A and B and the S signature of ABC transporters. The 
two half molecules are separated by a highly charged "linker 
region which is phosphorylated at several sites by protein 
kinase C and the first extracellular loop is heavily N-glyco-
sylated [3].Cancer Cell International 2005, 5:30 http://www.cancerci.com/content/5/1/30
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Recently, multiple MDR1 polymorphisms including more
than 20 single nucleotide polymorphism (SNP) have
been identified. The mutations at positions 2677(G→T)
and 2995(G →A) of MDR1 in normal cells were firstly
reported [158]. MDR1 polymorphism could be not only
associated with alteration of Pgp expression and/or func-
tion, drug disposition and treatment outcome but also
increase the risk of diseases such as Parkinson's disease
and ulcerative colitis [159]. The influence of MDR1
SNP(C3435T and G2677T) on disposition of Pgp
substrates or treatment outcome has been examplified in
digoxin, phenytoin, fexofenadine, nelfinarvir,
cyclosporine, talinolol and loperamide [159]. Polymor-
phisms of other ABC transporters have been reported
[160-163].
If a substance in food affects Pgp, this substance also
could affect the bioavailability of substrate drugs for Pgp.
It was reported that substances present in grape juice or
orange juice could increase the bioavailability of a drug
being the substrate of Pgp by inhibiting it. [164]. These
substances could also affect pharmacokinetics of other
drugs [160,165]. On the contrary, some drugs could
increase the expression of Pgp. St John's Wort used as an
antidepressant increases the expression of Pgp, so it could
significantly lower the serum concentration of indinavir
or cyclosporin [166]. Digoxin is the substrate of Pgp and
induces paclitaxel resistance by increasing Pgp [166]. Not
only Pgp but also MRP and BCRP could affect the bioa-
vailability of drugs.
Table 1: Gene locus and tissue distribution of ABC transporters
Name Alternate name Gene locus Tissue distribution
MDR1 ABCB1, P-GP 7q36 [9] Gut (apical membrane), liver (canalicular membrane), kindey (apical membrane of epithelial cells 
of proximal tubule), blood brain barrier (luminal membrane of endothelial cells), testis 
(endothelial cells of capillary), placenta (trophoblast)
MRP1 ABCC1 16p13.1 [6] Many tissues (brain etc)
MRP2 ABCC2, cMOAT 10q24 [10] Liver, gut, kidney, placenta
MRP3 ABCC3 17q21.3 [11] Liver, gut, adrenal cortex, placenta
MRP4 ABCC4 13q32 [11] Many tissues
MRP5 ABCC5 3q27 [11] Many tissues(brain etc)
MRP6 ABCC6 16p13.1 [12] Liver, kidney
MRP7 ABCC10 6p12-21 [13] Many tissues
MRP8 ABCC11 16q12.1 [14] Breast, testes
BCRP ABCG2, MXR1, ABCP 4q22 [15] Placenta (syncytiotrophoblasts), intestine (epithelium), liver (canalicular membrane), breast 
(ducts and lobules), endometrium (vein and capillary but not artery), gut
Table 2: Endogenous and exogenous substrates for ABC transporters
Name Endogenous substrate Exogenous cytotoxic substance
MDR1 Estrogen glucuronide conjugates (estradiol, estriol), endorphin, 
glutamate, steroids (cortisol, aldosterone, corticosterone), beta-
amyloid, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine 
(generically platelet-activating factor, PAF)
Anthracyclines (doxorubucin, daunorubicin, epirubicin), 
actinomycin D, colchicine, podophyllotoxin (etoposide, 
teniposide), methotrexate (only in carrier-deficient cells), 
mitomycin C, mitoxantrone, taxenes (paclitaxel, docetaxel), vinca 
alkaloids (vincristine, vinblastine)
MRP1 Estradiol-17beta(beta-D-glucuronide) glutathione, glutathione S-
conjugate leukoetriene C4, glucuronosyl bilirubin
Anthracyclines, cochicine, etoposide, heavy metals (arsenite, 
arsenate, antimonials), vincristine, vinblastine, paclitaxel
MRP2 Estradiol-17beta(beta-D-glucuronide), glutathione, glutathione S-
conjugate Leukoetriene C4, glucuronosyl bilirubin,
Cisplatin, CPT-11, doxorubicin, etoposide, methotrexate, SN-38, 
vincristine, vinblastine
MRP3 S-(2,4-dinitrophenyl)glutathione Cisplatin, doxorubicin, etoposide, methotrexate, teniopside, 
vincristine,
MRP4 Glucuronide and glutathione conjugates Methotrexate, nucleotide analogs, PMEA*
MRP5 Glutamate and phosphate conjugates Doxorubicin, methotrexate, nucleotide analogs, topotecan,
MRP6 Cyclic nucleotides (cAMP, cGMP), glutathione conjugate Doxorubicin, etoposide, teniposide
MRP7 ? ?
MRP8 17beta-estradiol-(17-beta-D-glucuronide), leukotriene C4, cyclic 
nucleotides
5'-Fluorouracil, 5'-fluoro-2'-deoxyuridine, 5'-fluoro-5'-
deoxyuridine, PMEA*
BCRP Heme or porphyrin Anthracyclines, bisantrene, camptothecin, epirubicin, flavopiridol, 
mitoxantrone, S-38, topotecan
* PMEA, 2',3'-dideoxycytidine 9'-(2'-hosphonylmethoxynyl)adenineCancer Cell International 2005, 5:30 http://www.cancerci.com/content/5/1/30
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One of the important physiological functions of efflux
pump present in the cell membrane is to provide a phar-
macological sanctuary for tissues present in the blood-tis-
sue barriers such as in the case of blood-brain barrier
(BBB), blood-placental barrier and blood-testes barrier.
Hydrophilic substances present in blood could not go
into tissues when they are not small enough to pass
through the tight junction with simple diffusion. None-
theless, various hydrophobic substances could not enter
these tissues because they are effluxed out by efflux
pumps. Actually, Pgp effluxes neurotransmitters or neuro-
modulators such as glutamate [148] and opioids
[149,167] into blood from the brain. Compared with
wild-type mice, drugs beings the substrate of Pgp were sig-
nificantly increased in the brain of fetus when the mdr1
gene is knocked out in mice [168-171]. When the BCRP
inhibitor, GF120918, was introduced to pregnant mice,
the topotecan level was increased by two-folds in mouse
fetus, suggesting that BCRP would function as the mater-
nal-fetal barrier in the placenta [172]. Thus, quantitative
and qualitative changes of transporters present in the
membrane could affect pharmacokinetics such as the dis-
tribution of endogenous and exogenous substances.
Structure of ABC transporters
Pgp is a 170-kDa membrane protein glycosylated at the
first extracellular loop (Fig. 1). Pgp is composed of 12
hydrophobic transmembrane domains (TMDs) and 2
nucleotide-binding domain (NBD). One NBD connects
two TMDs with a hydrophilic NBD loop. TDMs form
channels for substrate drugs, determine the characteristics
Comparison of nucleotide free-Pgp (nf-Pgp) and Pgp-AMP- PNP (Pgp-AMP-PNP) three-dimensional structures Figure 2
Comparison of nucleotide free-Pgp (nf-Pgp) and Pgp-AMP-
PNP (Pgp-AMP-PNP) three-dimensional structures. A, stereo 
pair of the nf-Pgp three-dimensional structure, displayed 
using netting at 1.0 σ (red) and 1.5 σ (yellow) above the mean 
density level and viewed perpendicular to the crystal plane 
from the more heavily stained side (corresponding to the 
extracellular surface). B, equivalent views of the Pgp-AMP-
PNP structure. The arrow indicates the gap along one side of 
the central pore. The locations of the three discrete densi-
ties A, B, and C are indicated. C, stereo pair of a side view of 
Pgp-AMP-PNP with the same color scheme as above. The 
directions of the principle crystallographic axes a and b are 
shown. Scale bar = 2.2 nm. AMP-PNP, non-hydralizable ATP 
analogue [176].
Model of the NBD conformational change by the drug bind- ing to TDM Figure 3
Model of the NBD conformational change by the drug bind-
ing to TDM. [178].Cancer Cell International 2005, 5:30 http://www.cancerci.com/content/5/1/30
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of substrate, and efflux substrate drugs whereas NBDs are
located in the interior of cytoplasm, and participate in
ATP binding and hydrolysis [173]. Pgp undergoes confor-
mational changes upon binding of nucleotide to the
NBDs [174]. Rosenberg et al. have analyzed the three-
dimensional structures of Pgp and its conformational
change in the presence and absence of nucleotide [175-
177]. The projection of the protein perpendicular to the
membrane is roughly rectangular with a maximum depth
of 8 nm, a pore size of 2.5 nm and two 3-nm lobes
exposed at the cytoplasmic face of the membrane. The
conformational change revealed a major reorganization
of the TMDs throughout the entire depth of the mem-
brane upon binding of nucleotide (Fig. 2A). In the
absence of nucleotide, the two TMDs form a single barrel
5–6 nm in diameter and about 5 nm deep with a central
pore that is open to the extracellular surface and spans
much of the membrane depth. Upon binding nucleotide,
the TMDs reorganize into three compact domains that are
each 2–3 nm in diameter and 5–6 nm deep (Fig. 2B). This
reorganization opens the central pore along its length in a
manner that could allow access of hydrophobic drugs
(transport substrates) directly from the lipid bilayer to the
central pore of the transporter [176].
When one of two NBDs of Pgp is inactivated, not only
drug transport but also ATP hydrolysis of normal NBD is
inhibited. This result indicates that two NBDs would func-
tion cooperatively and they could not hydrolyze ATP
independently [178]. It was recently reported that struc-
tural changes of NBDs are brought about when a drug
binds to TMD so that the distance between NBDs is
changed to affect the activity of ATPase as shown in Fig.
3[179]. Unlike in Pgp, however, the substrate leukotriene
C4 could not be transported once NBD2 is inactivated but
the substrate transport could not be inhibited when
NBD1 is inactivated in MRP1 [180]. This result suggests
that among ABC transporters, interactions of NBDs are
not simple but function differently for every transport.
Although the exact site and number of Pgp binding with
drugs have not yet been determined, the important bind-
ing sites such as TMD 4, 5, 6, 10, 11 and 12 have been
determined [181] whereas substrate drugs do not bind to
NBDs [182].
Development of chemosensitizers to overcome resistance
One of the causes for the failure of chemotherapy in the
treatment of cancer is the emergence of MDR. Once MDR
appears, chemotherapy is not effective even when using
high doses of drugs enough to overcome resistance, toxic
effects are brought about and the resistance mechanism
could be further stimulated. These problems could be
resolved by the use of the anticancer drugs that could
bypass the resistance mechanism. For example, we could
use other anticancer drugs such as alkylating drugs (cyclo-
phosphamide), antimetabolites (5-fluorouracil), and the
anthracycline modified drugs (annamycin and doxoru-
bicin-peptide) that would not function as the substrates of
ABC transporters [183-185]. The final method of over-
coming resistance is to administer substances inhibiting
ABC transporters with anticancer drugs at the same time.
These substances would reverse resistance against antican-
cer drugs to eventually being sensitized for anticancer
drugs so they are called chemosensitizers. They are also
called MDR modulators and MDR reverters. Chemosensi-
tizers against each transporter are summarized according
to the publishing years (Table 3). Of these, some are
chemosensitizers against one transporter and some others
against more than two transporters.
Many drugs such as the calcium channel blocker vera-
pamil and the immunosuppressant cyclosporin A would
inhibit resistance by functioning as competitive substrates
of Pgp regardless of their innate pharmacological func-
tions. Different clinical studies also showed that these
drugs could reverse resistance to anticancer drugs. Vera-
Proposed schematic model of NBDs showing the relative  positions of different nucleotide- and effector-binding sites Figure 4
Proposed schematic model of NBDs showing the relative 
positions of different nucleotide- and effector-binding sites. 
MANT-ATP binding is prevented by preincubation with anti-
progestin RU-486 and bound MANT-ATP is displaced by Ru-
486, suggesting the existence of a cytosolic steroidal-inter-
acting region adjacent to the ATP-binding site. Since the fla-
vonoid binding is prevented by preincubation with ATP and 
RU-486, bound flavonoids most likely cover both ATP site 
and the vicinal steroid site. MANT, 2'(3')-N-methylan-
thraniloyl [3].Cancer Cell International 2005, 5:30 http://www.cancerci.com/content/5/1/30
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pamil is the first reported chemosensitizer inhibiting
MDR [119] and its effect was also proven in the recent
clinical study [186]. However, verapamil brings about car-
diac toxicity at the concentration inhibiting resistance;
thus, in order to resolve this problem, the attempts were
made to develop (R)-verapmil [187] and verapamil ana-
logues having lower cardiac toxicity compared with (S)-
verapamil [188,189]. The immunosuppressant
cyclosporin A was first reported to reverse resistance by
acute leukemia against vincristine and daunorubicin
Table 3: Chemosensitizers inhibiting Pgp, MRP and BCRP
Name Year Chemosensitizer
Pgp 2004 Benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates [16], diallyl sulfide [17], PK11195 [18], small scFv recombinant 
Pgp antibody fragment [19]
2003 Amooranin [20], etrandrine, fangchinoline [21], ginsenoside Rg(3) [22], KR30031 [23], methylenedioxyethylamphetamine [24], 
protopanaxatriol ginsenosides [25], saquinavir [26], siRNA of mdr1 gene [27, 28], tRA 98006* [29]
2002 3,5-dibenzoyl-1,4-dihydropyridines[30], PKC412 [31], pyronaridine [32], sinensetin [33]
2001 Agosterol A [34], haloperidol and dihydrohaloperidol [35], SB203580 [36], tropane alkaloid esters [37], SNF4435C and D [38], 
tea polyphenol [39], trans-N,N'-bis(3,4-dimethoxybenzyl)-N-solanesyl-1,2-diaminocyclo hexane (N-5228) [40]
2000 Astemizole [41], atorvastatin [42], 7-O-benzoylpyripyropene A [43], 5-O-benzoylated taxinine k [44], clarithromycin and 
YM17K (3,4'-dideoxy mycaminosyl tylonolide hydrochloride) [45], cyclopamine and tomatidine[46], 3,5-diacetyl-1,4-
dihydropyridines [47], 7, 8-dihydroxy-3-benzazepine [48], doxorubicin-gallium-transferrin conjugate [49], macrolide 
antibiotics (josamycin, tamolarizine) [50], nelfinavir [51] norverapamil [52], ontogen (ONT-093, formerly OC-144-093) [53], 
R101933 [54], taxuspine C, 2'-desacetoxyaustrospicatine and 2-desacetoxytaxinine [55], V-104 [56]
1999 D-alpha-tocopheryl polyethylene glycol 1000 succinate [57], anti-MDR1 ribozymes [58], AR-2 [59], carvedilol [60], 
erythromycin [61], ketoconazole [62], kopsiflorine [63], nomegestrol [64], PAK-200S [65], pluronic block copolymer [66], 
reversin [67], ritonarvir [68], rosemary extract [69], TTD [70], XR9576(2) [71]
1998 Ardeemins [72], AV200 [73], 5-O-benzoylated taxuspine C [74], bromocriptine [75], dipyridamole [76], droloxifene [77], 
imidazothiazole derivatives (N276-12, N276-14, N276-17) [78], oxalyl bis(N-phenyl)hydroxamic acid [79], tetrandine and 
fangchinoline [21], tiamulin [80], XR9051 [81]
1997 Biricodar (VX-710; Incel) [82, 83], cyproheptadine [84]
1996 CL 329,753 [85], indole-3-carbinol [86], itraconazole [87], LY335979 [88], medroxyprogesterone [89], mefloquine [90], 
mifepristone (RU-486) [91], reserpine [92]
1995 Azelastine and flezelastine [93], B9209-005 [94], dexniguldipine (B8509-035) [95], dexverapamil [96], epidermal growth factor 
(EGF), insulin-like growth factor I (IGF-I) [97], quercetin [98]
1994 MS-209 [99], pentoxifylline [100], Ro11-2933 (DMDP) [101], RU486 [102]
1993 Dilantin [103], GF120918[104], meperidine, pentazocine, and methadone [105], Pgp monoclonal antibodies and antisense 
oligonucleotide [106], tamoxifen and toremifene [107]
1992 Staurosporine and NA-382 [108]
1991 Biperidil [109], SDZ PSC 833[110]
1990 Cremophor EL [111]
1989 Cefoperazone, cetriaxone [112], phenothiazine [113], YM534 [114]
1987 Diltiazem[115], cyclosporine A [116]
1986 Aamiodarone [117]
1984 Quinidine [118]
1981 Verapamil [119],
MRP 2004 benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates [16]
2003 tRA 98006 [29]
2001 Agosterol A [34]
2000 5-O-benzoylated taxinine k [44], 4-deacetoxyagosterol A [120], doxorubicin-gallium-transferrin conjugate [49], V-104 
[56], pluronic block copolymer [66], quinoline-based drugs (chloroquine, quinine, quinidine, and primaquine) [121],
1999 dipyridamole [122], erythromycin and ofloxacin [123], mifepristone (RU-486) [124], MS-209 [125], rifampicin [126]
1998 Biricodar (VX-710; Incel) [83], imidazothiazole derivatives (N276-12, N276-14, N276-17) [78], NSAIDs 
(indomethacin, sulindac, tolmetin, acemetacin, zomepirac and mefenamic acid) [127], ONO-1078 [128], quercetin [98]
1997 Indomethacin [129], probenecid [130]
1996 Acrolein and chloroacetaldehyde [131], d,l-buthionine-(S,R)-sulfoximine [132], itraconazol [87], PAK-104P [133]
1995 Difloxacin [134], MK571 [135]
BCRP 2004 Chrysin and biochanin A [136], genistein and naligenin [137], Imatinib mesylate (Gleevec, STI571) [138]
2003 Estrone, diethylstilbestrol and TAG-139 [139], tRA 98006 [29]
2002 Ko143 [140]
1999 GF120918 [141]
1998 fumitremorgin C [142]
* Boldface compounds indicate chemosensitizers inhibiting more than two transportersCancer Cell International 2005, 5:30 http://www.cancerci.com/content/5/1/30
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[190]. Following cyclosporin A, researchers found that
other immunosuppressants including FK506 and
rapamycin could inhibit MDR [191]. However, when
cyclosporin A is applied clinically, researchers placed
efforts to develop cyclosporin analogues having few side
effects due to their innate immuno suppressant effects and
hepatic and renal toxicity with excellent chemosensitizing
effects. As a result, PSC-833 (Valspodar), which is the
non-immune suppressant analogue of cyclosporin, was
developed [110]. In addition to non-immunosuppressant
effect, its chemosensitivity is about 10 times higher than
that by cyclosporin in Pgp-mediated MDR, so clinical
studies are being performed on this drug [192]. Among
those drugs having their innate pharmacological activities
such as verapamil and cyclosporin A, those having chem-
osensitizing effect is called the first-generation chemosen-
sitizers. The problems related with the first-generation
chemosensitizers are that they generally show low effects
and high toxicity at resistance-inhibiting doses. In order to
supplement these problems, the chemosensitizers devel-
oped only for chemosensitizing effects are called the sec-
ond-generation chemosensitizers, which include PSC-
833, VX-710, LY335979, XR9051 and XR9576 [193].
Multi-national companies are pursuing the development
of second-generation chemosensitizers by overcoming the
problems of existing chemosensitizers (low effects, side
effects, and drug-drug interaction), and some of these
chemosensitizers are in the process of being tested
clinically.
Most chemosensitizers bind with TMD in transporter, but
steroid and flavonoid are new recently introduced chem-
osensitizers, which inhibit transporters by binding with
NBD. The binding site of steroid is different from the
binding site of ATP but is probably in the vicinity of the
ATP binding site [194]. On the other hand, the flavonoid,
kaempferide, is bifunctional in that it would partially
block the binding of the antiprogestin RU-486 in the cyto-
plasm domain of Pgp and block ATP binding [195] (Fig.
4). Recently, flavonoid chemosensitizers reversing Pgp-
mediated MDR have been screening. It is believed that fla-
vonoid chemosensitizers have a significant advantage
with respect with a therapeutic index (Table 4). These may
be second-generation flavonoid chemosensitizers [33].
The fungal toxin, fumitremorgin C (FTC), is a strong
inhibitor of BCRP but its use in vivo has been limited due
to its neurotoxicity [196]. It was recently reported that the
tetracyclic analogue of FTC, Ko143, is the most strong
chemosensitizer aginst BCRP having little toxicity [140].
Since ABC transporters can be coexpressed in some types
of cancer cells, the development of chemosensitizers
against MRP and/or BCRP as well as Pgp has been highly
demanding. These include VX-710 against Pgp and MRP
[82,83], GF120918 against Pgp and BCRP [104,141] and
tRA98006 against all three transporters [29].
Conclusion
One of the major causes of failure in anticancer chemo-
therapy is resistance against anticancer drugs. Overexpres-
sion of ABC transporters such as Pgp, MRP and BCRP has
been shown to be responsible for the major portion of
MDR. Therefore elucidation of the structure and the
function for each ABC transporter is prerequisite for
understanding how these transporters work and for
reversing MDR. One strategy for reversal of MDR cells
expressing ABC transporters is combined use of anticancer
drugs with chemosensitizers. Second-generation chemo-
sensitizers have been developed for the purpose of obtain-
ing higher efficacy and lower toxicity than first-generation
chemosensitizers. Inhibitors of ABC transporters can be
exploited to enhance the oral bioavailablilty or the brain
penetration of various drugs.
Combination of a conventional anticancer chemotherapy
with new strategies such as chemosensitizers, receptor-
mediated targeting and nanotechnology will shed light on
cancer patients in the near future.
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